STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
Why this matters: health reporting relevant to everyday decisions and well-being.
CHICAGO — The biotech company Revolution Medicines has begun sending its experimental, life-extending treatment for pancreatic cancer to physicians and their patients under an early access program authorized by the Food and Drug Administration, the company’s CEO Mark Goldsmith told STAT. “We are now shipping the drug,” he said, speaking Friday evening at a STAT event held in conjunction with the annual meeting of the American Society of Clinical Oncology.&#x A0; The drug, daraxonrasib, is not yet approved. But patients with pancreatic cancer have been clamoring for it since mid April, when Revolution reported the striking results of a Phase 3 clinical trial. Patients treated with daraxonrasib lived nearly twice as long as patients offered standard chemotherapy — an outcome unprecedented in the pancreatic cancer field. Continue to STAT+ to read the full story…